Skip to content
Back to Investors
OI

Oxford Innovation EIS Growth Fund

Venture Capital

Oxford Innovation EIS Growth Fund invests in innovative early-stage companies with strong growth potential.

Portfolio

6

companies

By category

  • BioTech£4.3M
  • SensorTech£2.8M
  • ManuTech£1.0M
  • CleanTech£950K
  • HealthTech£2

By location

  • Cambridge£4.3M
  • United Kingdom£2.8M
  • Oxford£2.0M

Portfolio companies

CG

Cognitant Group

Cognitant Group provides a digital health platform that connects patients with reliable treatment information and clinical services.

E

EcoSync

EcoSync deploys cloud-based energy management technology to reduce commercial heating bills and carbon emissions.

EC

Exact Comms

Exact Comms builds contactless technology for real-time facility monitoring.

I

Interpac

Interpac manufactures low-cost and sustainable cold corrugation machines for producing corrugated board.

Qkine

Qkine

Qkine manufactures specialist bioactive proteins for stem cell and regenerative medicine applications.

SM

Silicon Microgravity

Silicon Microgravity develops inertial and gravity sensors using micro-electrical mechanical systems technology.


Recent investments

The investment comes from the Oxford Innovation EIS Growth Fund and OION Angels to support international expansion and product development.

"We’re excited to have Oxford Innovation Finance supporting us with not just capital, but a depth of experience and an extensive network along with it. We’re at an important stage in our growth, moving from proving the technology to deploying it with customers across multiple markets, and we’re now focused on building partnerships, product capability and the international presence needed to effectively scale."
— Peter McCaul, Founder and CEO
Other
£1.0M

Oxford Innovation EIS Growth Fund has backed the manufacturer of cold corrugation equipment in a follow-on funding round.

"Despite appearances, corrugated board is not easy to make and over the last 50 years there has been little to no innovation in the manufacturing process. With the majority of global goods now being bought online and demand for sustainable packaging increasing, it was time for a revolutionary solution to the current energy and water intensive manufacturing processes. Our cold corrugation process uses 80% less energy, is one tenth of the price, and allows for decentralised, on-demand production that reduces manufacturing costs by up to 30%. This recent investment will allow us to continue the manufacture of our innovative machines and enable more customers to harness the benefits of self-manufacturing their corrugated board more sustainably."
— Charles Smith, Co-founder and MD
Other
£2.8M

The funding was backed by the UK Innovation & Science Seed Fund, Oxford Innovation EIS Growth Fund, Oxford Innovation Finance's Angel Network, and the Defence and Security Accelerator.

"This new investment provides us with the funding to take our game changing technology to commercialisation, helping deliver the UK government’s semiconductor and technology strategy. Our Inertial sensors are already gaining strong industry interest globally with a major aerospace and defence contractor having already placed contracts. Our revolutionary gravity sensor will be commercialised later this year with the industry interest shown by our acceptance on to Europe’s largest infrastructure accelerator program and the award of funding from the Department for Business and Trade railway construction innovation competition. We are very excited for this next stage in SMG’s journey."
— Francis Neill, Chief Executive Officer and Director
Other
£2

Oxford Innovation and OION angels have backed Cognitant Group in a follow-on funding round.

"We are focused on making it easier for patients to understand their symptoms and management of their individual condition. This not only has a positive impact on their overall health, but it also allows them to successfully make decisions about their individual treatment plans in collaboration with their clinicians. Our partnerships with global pharmaceutical companies, the NHS and other healthcare providers, is making real and valuable changes to the way patients engage with and manage their health."
— Tim Ringrose, CEO
£4.3M

The oversubscribed round will scale up manufacturing and research for the bioactive protein developer.

"We are at an exciting stage of development, with new funds facilitating our next phase of rapid growth as we continue our mission of providing more reliable tools for research and bio-manufacturing. Our platform provides an improved process for complex protein manufacture at exceptionally high purity and unique engineered products that address specific challenges for stem cell biology. Growth factors are essential reagents for all stem cell manufacturing, and therefore critical for the delivery of cell therapies and cultivated meats."
— Catherine Elton, CEO and Founder